Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Consensus Rating of “Moderate Buy” by Analysts

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has been given an average recommendation of “Moderate Buy” by the six analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $67.50.

Several equities analysts have weighed in on the stock. Canaccord Genuity Group lifted their price objective on shares of Eton Pharmaceuticals from $60.00 to $68.00 and gave the stock a “buy” rating in a research report on Friday, August 14th. Craig Hallum raised their target price on Eton Pharmaceuticals from $40.00 to $62.00 and gave the company a “buy” rating in a report on Tuesday, July 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a report on Friday, July 17th. Zacks Research upgraded shares of Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, August 24th. Finally, B. Riley Financial reaffirmed a “buy” rating and issued a $70.00 target price (up from $40.00) on shares of Eton Pharmaceuticals in a report on Friday, August 14th.

Eton Pharmaceuticals Stock Performance

ETON stock opened at $59.78 on Monday. Eton Pharmaceuticals has a fifty-two week low of $14.27 and a fifty-two week high of $66.37. The company has a quick ratio of 1.30, a current ratio of 1.52 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $1.71 billion, a P/E ratio of 157.32 and a beta of 0.86. The company has a 50-day simple moving average of $45.17 and a 200 day simple moving average of $32.02.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its earnings results on Thursday, August 13th. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.24. The business had revenue of $37.59 million during the quarter, compared to analysts’ expectations of $27.11 million. Eton Pharmaceuticals had a return on equity of 40.13% and a net margin of 12.02%. Sell-side analysts predict that Eton Pharmaceuticals will post 1.13 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Eton Pharmaceuticals news, insider David Krempa sold 25,000 shares of Eton Pharmaceuticals stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $65.07, for a total transaction of $1,626,750.00. Following the transaction, the insider directly owned 37,025 shares in the company, valued at approximately $2,409,216.75. The trade was a 40.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Paul V. Maier sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $59.07, for a total value of $2,953,500.00. Following the completion of the sale, the director owned 59,745 shares in the company, valued at $3,529,137.15. The trade was a 45.56% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 125,000 shares of company stock valued at $6,204,250. 16.49% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Eton Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. Deutsche Bank AG lifted its stake in Eton Pharmaceuticals by 4.9% in the 4th quarter. Deutsche Bank AG now owns 18,249 shares of the company’s stock valued at $309,000 after purchasing an additional 850 shares during the last quarter. Toth Financial Advisory Corp acquired a new position in Eton Pharmaceuticals during the 2nd quarter valued at about $43,000. Intech Investment Management LLC boosted its stake in shares of Eton Pharmaceuticals by 11.1% in the 4th quarter. Intech Investment Management LLC now owns 12,421 shares of the company’s stock worth $210,000 after buying an additional 1,244 shares during the last quarter. State of Wyoming raised its position in Eton Pharmaceuticals by 16.4% in the first quarter. State of Wyoming now owns 9,498 shares of the company’s stock worth $234,000 after acquiring an additional 1,337 shares during the period. Finally, Man Group plc boosted its position in Eton Pharmaceuticals by 6.0% during the second quarter. Man Group plc now owns 23,754 shares of the company’s stock worth $338,000 after purchasing an additional 1,350 shares during the period. Institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.